secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001193125-22-096176
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Steven Paul, M.D. to retire from Alnylam Board effective April 16, 2022
--------------------------------------------------------------------------------

- Steven Paul resigns from Board effective April 16, 2022; no disagreement with company operations.
- Board size reduced from 11 to 10 members upon Dr. Paul's departure.
- Colleen F. Reitan joins PC&C Committee; Amy W. Schulman remains Chair.
- Dr. Paul served on Alnylam Board since September 2010; praised for decade of service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522096176/0001193125-22-096176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522096176/d343633d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-096176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer